{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:08:30Z","timestamp":1785802110001,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.transproceed.2023.02.043","type":"journal-article","created":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T18:37:13Z","timestamp":1679769433000},"page":"1305-1309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression"],"prefix":"10.1016","volume":"55","author":[{"given":"Amit S.","family":"Pasari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-6953","authenticated-orcid":false,"given":"Manish R.","family":"Balwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Gurjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charulata","family":"Bawankule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Bhawane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Tolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranjal","family":"Kashiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay M.","family":"Katekhaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2023.02.043_bib0001","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/cts.13206","article-title":"A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients","volume":"15","author":"Bunthof","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101741","article-title":"Systematic review and meta-analysis of calcineurin inhibitors on long-term prognosis of renal transplant patients","volume":"75","author":"Yang","year":"2022","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0003","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2165\/00003495-199346040-00009","article-title":"A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation","volume":"46","author":"Peters","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0004","first-page":"e14879","article-title":"Exposure to tacrolimus trough levels below 6 ng\/ml during the first year is associated with inferior kidney graft survival","author":"Agur","year":"2022","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/fcp.12432","article-title":"Tacrolimus overexposure in kidney transplant recipients during the first post-operative week: caution is required in older patients","volume":"33","author":"Lemaitre","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0006","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/cpt.2163","article-title":"Avoiding tacrolimus underexposure and overexposure with a dosing algorithm for renal transplant recipients: a single arm prospective intervention trial","volume":"110","author":"Francke","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0007","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.3390\/jcm11216320","article-title":"Comparison of tacrolimus intra-patient variability during 6-12 months after kidney transplantation between CYP3A5 Expressers and Nonexpressers","volume":"11","author":"Nuchjumroon","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0008","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.transproceed.2022.07.009","article-title":"Frequencies and association of CYP3A5 polymorphism with tacrolimus concentration among renal transplant recipients in Vietnam","volume":"54","author":"Xuan","year":"2022","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0009","doi-asserted-by":"crossref","first-page":"e13248","DOI":"10.1111\/petr.13248","article-title":"Effect of CYP3A5*1 expression on tacrolimus required dose for transplant pediatrics: a systematic review and meta-analysis","author":"Hendijani","year":"2018","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0010","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41397-019-0144-7","article-title":"CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis","volume":"20","author":"Khan","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0011","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40262-020-00955-2","article-title":"Clinical impact of the adaptation of initial tacrolimus dosing to the CYP3A5 genotype after kidney transplantation: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Yang","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0012","first-page":"e14893","article-title":"Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers","author":"Reininger","year":"2022","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0013","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/ijn.IJN_97_18","article-title":"Influence of CYP3A5 and ABCB1 polymorphism on tacrolimus drug dosing in South Indian renal allograft recipients","volume":"29","author":"Fernando","year":"2019","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ekir.2019.09.013","article-title":"Melding pharmacogenomic effect of mdr1 and cyp3a5 gene polymorphism on tacrolimus dosing in renal transplant recipients in northern India","volume":"5","author":"Prasad","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0015","doi-asserted-by":"crossref","first-page":"P98","DOI":"10.1186\/1755-8166-7-S1-P98","article-title":"Influence of CYP3A5 polymorphism on tacrolimus drug dosing in Indian renal allograft recipients: initial experience","volume":"7","author":"Patel","year":"2014","journal-title":"Mol Cytogenet"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0016","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/ijp.ijp_279_21","article-title":"Evaluation of genetic polymorphism of CYP3A5 in normal healthy participants from western India\u2014a cross-sectional study","volume":"54","author":"Maurya","year":"2022","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0017","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1097\/01.tp.0000886148.09080.cd","article-title":"CYP3A5 polymorphism in renal transplantation: a key to personalized medicine","volume":"106","author":"Gurjar","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0019","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.transproceed.2009.01.097","article-title":"Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus","volume":"41","author":"Chen","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0020","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/ndt\/gfr253","article-title":"CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on tacrolimus dose requirements and clinical outcome after renal transplantation","volume":"26","author":"Glowacki","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0021","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/bcp.13980","article-title":"Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients","volume":"85","author":"Anutrakulchai","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1037566","article-title":"Combined impact of the inter and intra-patient variability of tacrolimus blood level on allograft outcomes in kidney transplantation","volume":"13","author":"Park","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0023","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/FPC.0b013e32834a48ca","article-title":"Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers","volume":"21","author":"Tang","year":"2011","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0024","doi-asserted-by":"crossref","first-page":"e17312","DOI":"10.1097\/MD.0000000000017312","article-title":"Risk factors and etiology of repeat infection in kidney transplant recipients","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0025","doi-asserted-by":"crossref","first-page":"S498","DOI":"10.1016\/j.ekir.2022.07.093","article-title":"POS-075 association of CYP3A5 polymorphism with infections in kidney transplant recipients","volume":"7","author":"Patil","year":"2022","journal-title":"Kidney Int Reports"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0026","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1399-0012.1997.tb00812.x","article-title":"Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients","volume":"11","author":"Katari","year":"1997","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0027","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/medicina57030250","article-title":"New-onset diabetes after kidney transplantation","volume":"57","author":"Ponticelli","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0028","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1556\/APhysiol.101.2014.3.13","article-title":"Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation","volume":"101","author":"Borda","year":"2014","journal-title":"Acta Physiol Hung"},{"key":"10.1016\/j.transproceed.2023.02.043_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.726784","article-title":"Pharmacogenetics based dose prediction model for initial tacrolimus dosing in renal transplant recipients","volume":"12","author":"Srinivas","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134523001045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134523001045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:54:28Z","timestamp":1729126468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134523001045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0041134523001045"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.02.043","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.02.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}